Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Up 5.8% in January

Atossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) saw a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 9,250,000 shares, a growth of 5.8% from the January 15th total of 8,740,000 shares. Based on an average trading volume of 876,500 shares, the days-to-cover ratio is presently 10.6 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC boosted its holdings in Atossa Therapeutics by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,814,446 shares of the company's stock valued at $4,278,000 after acquiring an additional 44,762 shares during the period. State Street Corp lifted its holdings in Atossa Therapeutics by 4.2% in the 3rd quarter. State Street Corp now owns 1,732,221 shares of the company's stock worth $2,633,000 after buying an additional 69,180 shares during the period. Renaissance Technologies LLC grew its position in shares of Atossa Therapeutics by 18.9% in the 4th quarter. Renaissance Technologies LLC now owns 1,557,632 shares of the company's stock worth $1,471,000 after buying an additional 247,562 shares during the last quarter. Northern Trust Corp increased its stake in shares of Atossa Therapeutics by 7.5% during the fourth quarter. Northern Trust Corp now owns 1,025,724 shares of the company's stock valued at $968,000 after buying an additional 71,525 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in Atossa Therapeutics by 141.4% in the fourth quarter. JPMorgan Chase & Co. now owns 361,296 shares of the company's stock worth $341,000 after acquiring an additional 211,654 shares during the period. 12.74% of the stock is owned by institutional investors.

Atossa Therapeutics Price Performance

ATOS stock traded down $0.04 during mid-day trading on Thursday, hitting $0.84. 427,504 shares of the stock were exchanged, compared to its average volume of 743,756. The business has a fifty day moving average price of $0.92 and a 200 day moving average price of $1.21. Atossa Therapeutics has a 12 month low of $0.72 and a 12 month high of $2.31. The stock has a market capitalization of $105.67 million, a price-to-earnings ratio of -3.82 and a beta of 1.24.

Wall Street Analyst Weigh In

ATOS has been the topic of a number of analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $7.00 target price on shares of Atossa Therapeutics in a report on Thursday, January 30th. StockNews.com downgraded Atossa Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday, November 18th. Finally, Ascendiant Capital Markets boosted their target price on Atossa Therapeutics from $6.50 to $7.00 and gave the stock a "buy" rating in a research report on Monday, December 9th.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.